logo
Can adults grow new brain cells?

Can adults grow new brain cells?

Yahoo2 days ago

When you buy through links on our articles, Future and its syndication partners may earn a commission.
The developing human brain gains billions of neurons while in the womb, and tacks on some more during childhood. For most of the 20th century, the conventional wisdom was that the brain cells grown before adulthood would be the only ones we would have for the rest of our lives. But over the past few decades, more and more research is challenging that belief.
So is it actually possible for adults to grow neurons? While some experts believe there's strong evidence that we can gain brain cells after childhood, others are still skeptical of this notion.
The process of creating new brain cells is called neurogenesis. Researchers first observed neurogenesis after birth in lab animals of various ages, including mice, rats and songbirds. In adult mice, they found new neurons growing in parts of the brain collectively called the subventricular zone, an area closely linked with sense of smell, as well as in the hippocampus, a structure that's central to memory.
Researchers think that neurogenesis in these brain regions is important for plasticity, or the brain's ability to adapt and change over time. Plasticity underlies the ability to learn and form memories, for instance.
In mice, it's clear that lifestyle factors such as living in a stimulating environment and exercising can promote the growth of new neurons. Conversely, in mouse models of diseases like Alzheimer's, neurogenesis is hampered. What's still up for debate is whether these findings extend beyond mice and other lab animals.
"Most of our knowledge about adult neurogenesis came from studies in animal models," Hongjun Song, a professor of neuroscience at the University of Pennsylvania Perelman School of Medicine, told Live Science in an email. "Whether such knowledge can be directly translated to human studies is a challenge."
That's because many of the studies that have established the existence of adult neurogenesis in animals used methods that aren't possible in human studies, such as injecting radioactive tracer molecules into the brain. These methods enable scientists to visualize if and where new neurons are growing, but the tracers themselves can be toxic. These methods also require dissecting the brain after the animal has been euthanized.
"Unfortunately, there is no way to measure neurogenesis in the living person yet," Gerd Kempermann, a professor of genomics of regeneration at the Center for Regenerative Therapies in Dresden, Germany, told Live Science in an email.
Related: Is there really a difference between male and female brains? Emerging science is revealing the answer.
There are, however, some rare cases in which scientists have been able to apply similar methods to track neurogenesis in humans. For example, the radioactive tracer molecules used in animal neurogenesis studies are also sometimes used by doctors to track tumor growth in patients with brain cancer. While these radioactive tracer molecules are too toxic to give to healthy people, their benefits outweigh their risks in patients who already have cancer.
Scientists behind a 1998 study published in the journal Nature Medicine used this approach and analyzed the brains of cancer patients after their deaths. They reported that, in addition to flagging cancer cells, the tracer molecules had marked new neurons in the hippocampus. This finding suggested that humans could grow new neurons well into adulthood, given the patients were 57 to 72 years old.
Later, a 2013 study in the journal Cell used a form of radiocarbon dating to look for new neurons in humans. Radiocarbon dating usually determines the age of a sample by comparing the relative proportion of two different forms of carbon, or carbon isotopes, called carbon-14 and carbon-12. But to study neurogenesis in humans, scientists instead looked at carbon-14 concentrations inside the DNA of cells.
Their approach took advantage of the fact that there was a spike in carbon-14 levels in the atmosphere caused by nuclear bomb tests in the 1950s and 1960s. People's bodies absorbed this carbon-14 via their diets, and it became incorporated into their DNA. The amount of carbon-14 in a given cell corresponds to the isotope's concentrations in the atmosphere at the time the cell formed, making it possible to roughly pinpoint the "birthday" of that cell — and determine whether it formed after its owner's birth.
By analyzing postmortem brain tissue from people ages 19 to 92, this radiocarbon study identified newborn neurons in the adult hippocampus. But while compelling, the study's methods were so complex that the results have never been replicated.
That said, there are also more indirect markers of neurogenesis, such as certain proteins that are only present in growing neurons. Using these methods, both Kempermann and other research groups have uncovered additional evidence of newborn neurons in the adult human brain.
"There are many different markers that are more or less specific for adult neurogenesis," Kempermann said. "In tissue sections, one can study these markers under the microscope and look for patterns that are consistent with neuronal development."
But some researchers aren't convinced by this evidence. Arturo Alvarez-Buylla, a professor of neurological surgery at the University of California, San Francisco, has spent his career studying the growth of new neurons. While he's observed new neurons being formed in children and adolescents, he's found little evidence to support the notion of neurogenesis in adults.
Alvarez-Buylla believes there are a number of issues that may lead other researchers to find signs of neurogenesis in adult humans. For example, the chemical markers that some labs use to track new neurons may also show up in other cell types, such as glia, which are cells in the brain that support neurons' function in various ways. This may make it appear that new neurons are growing when they're actually not.
He's also skeptical of the use of carbon-14 dating for this purpose, calling it "creative" but arguing that researchers can't confirm that the new cells are neurons, or if there could be other potential reasons for varying carbon-14 levels in cells.
But Alvarez-Buylla isn't ruling out the possibility of human adult neurogenesis; he's only saying that — so far — the evidence hasn't convinced him. "I would say that is a rare phenomenon," said Alvarez-Buylla. "If it happens, it's very, very few cells."
Kempermann, on the other hand, is a firm believer that people can grow new neurons well into adulthood. "The positive reports outnumber the critical papers by far, their take is much wider, and their quality is overall higher."
The researchers said that understanding whether adult neurogenesis exists will continue to be a key question for the field of neuroscience.
RELATED STORIES
—Could we ever retrieve memories from a dead person's brain?
—What happens in your brain while you sleep?
—How much of your brain do you need to survive?
"The question about whether adults can grow new neurons has tremendous implications for the plasticity of the adult brain," Song said. If new neurons can be grown and integrated into the brain, he explained, those mechanisms could form the basis for new therapies for a variety of conditions, including brain injuries and neurodegenerative disorders.
Alvarez-Buylla said that even if he doesn't believe neurogenesis happens frequently in adults, it may nonetheless be possible to harness the mechanisms used by animals to grow new neurons for human therapies.
"The whole idea that it can happen opens a huge door for repair," he said. "I hope that we can keep our plasticity open to things going either way."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes

Associated Press

time41 minutes ago

  • Associated Press

Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes

Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the 'Company'), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran's Science Advisor Prof. Avraham Mayevsky's book titled The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiological States was published by a publishing house, Springer. It is available by eBook or Hardcover. The publication serves as a scientific cornerstone for Bioxytran's clinical development program of the universal oxygen carrier (UOC) in ischemic stroke and Alzheimer's disease, and is directly tied to the use of the MDX Viewer as an analytical method to detect a brain regions response to the addition of a UOC. The device has FDA approval to measure tissue oxygenation. Bioxytran is pioneering a transformative approach to treating ischemic stroke and neurodegenerative disease. The UOC is capable of replacing hyperbaric oxygen treatment (HBOT) by efficiently delivering therapeutic type of oxygen at the cellular level versus a charged version of oxygen prevalent in HBOT treatment called reactive oxygen species (ROS). This breakthrough is powered by the MDX viewer that provides real-time metabolic insights – a crucial element of Bioxytran's regulatory approach. The Mongolian gerbil brain is special in that it lacks the vasculature compensatory mechanisms that can deal with decreased blood flow in the event of a stroke. Since the blood vessels in the Mongolian gerbil brain have no coping mechanism it makes them ideal in studying stroke pathophysiology. The research compiled in this publication further validates Bioxytran's scientific and clinical approach, positioning the company on the cutting edge of advancements in brain health and neuroprotective treatments. 'This research is paving the way for substantial advances in the understanding of the pathology of stroke and other neurodegenerative diseases, said Avraham Mayevsky, Member of Bioxytran's Medical Advisory Board. 'One of the biggest challenges in in clinical trials is determining the efficacy of a drug. This gerbil brain model has great predictive value in ischemic stroke and Alzheimer's disease. The gerbil model coupled with the MDX Viewer will provide us amazing insight in the pathogenesis of stroke and neurodegenerative diseases. Over 60 years went toward the development of the book which highlights a model of how brain anomalies are detected using this device.' About Bioxytran, Inc. Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over 90%. For more information, visit Investor Relations Michael Sheikh 509-991-0245 [email protected] Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words 'believe,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'plan,' and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share
Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share

Forbes

timean hour ago

  • Forbes

Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share

Amazon Pharmacy is rolling out new features in hopes of attracting more seniors covered by Medicare's drug benefit, a potentially lucrative market dominated by CVS Health and Walgreens. In an announcement Tuesday, Amazon said it is launching a new 'caregiver support feature' that allows its customers to have someone else manage medications on their behalf. Once the caregivers are verified through a secure invitation, 'caregivers can now manage medications for their loved ones,' the company said. In addition, customers with Medicare Part D drug coverage can now access PillPack, Amazon's online pharmacy that is designed to simplify medication management, particularly for multiple prescriptions via pre-sorted and labeled packets delivered directly to patients' doors. It's the latest effort by the online retail giant Amazon to invest in its pharmacy business, which Drug Channels Institute estimates generated 'less than $2 billion in 2024 revenue - just 0.3% of the total prescription dispensing market.' Amazon doesn't disclose how many prescriptions it fills or financial information regarding its pharmacy and healthcare businesses. Amazon, which purchased PillPack seven years ago this month for more than $750 million, has yet to disclose revenues for its Amazon Pharmacy business in the parent company's quarterly earnings statements. In contrast, CVS filled 435 million prescriptions in the first quarter for an increase of 4.3% from the year ago period while Walgreens filled more than 309 million prescription in its most recent quarter, up 3.4%. Combined, Walgreens and CVS generated more than $370 billion in prescription revenues last year, According to Dryg Channels. CVS and Walgreens have the largest share of the U.S. prescription market by most measures at a combined 40% while Amazon's share is less than 1%, according to some studies. Neither CVS nor Walgreens would disclose how many Medicare Part D prescriptions the companies fill. By adding features for seniors, Amazon Pharmacy is looking to tap a Medicare prescription market growing by thousands every day. More than 11,000 Americans are turning 65 every day. Amazon is also trying to find a niche with Americans who are caring for an elderly family member. More than 50 million people in the U.S. 'are taking care of an aging family member,' Amazon said citing data from AARP. The aging population, coupled by industry statistics showing up to one-third of Americans don't take their medications as directed or never fill them. 'These updates deliver what our customers have been asking for—simpler medication management for themselves and their loved ones,' Amazon Pharmacy vice president John Love said. 'Whether you're a caregiver juggling multiple prescriptions for an aging parent, or a customer who could benefit from the convenience of pre-sorted packets delivered reliably each month, we're removing barriers and making pharmacy work better for you.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store